- Home
- CARV vs NLSP Comparison
CARV vs NLSP Comparison
Compare CARV & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- NLSP
- Stock Information
- Founded
- CARV 1948
- NLSP 2015
- Country
- CARV United States
- NLSP Switzerland
- Employees
- CARV N/A
- NLSP N/A
- Industry
- CARV Savings Institutions
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- NLSP Health Care
- Exchange
- CARV Nasdaq
- NLSP Nasdaq
- Market Cap
- CARV 13.2M
- NLSP 12.4M
- IPO Year
- CARV 1994
- NLSP 2021
- Fundamental
- Price
- CARV N/A
- NLSP $1.87
- Analyst Decision
- CARV
- NLSP
- Analyst Count
- CARV 0
- NLSP 0
- Target Price
- CARV N/A
- NLSP N/A
- AVG Volume (30 Days)
- CARV 27.8K
- NLSP 943.2K
- Earning Date
- CARV 11-13-2025
- NLSP 10-06-2025
- Dividend Yield
- CARV N/A
- NLSP N/A
- EPS Growth
- CARV N/A
- NLSP N/A
- EPS
- CARV N/A
- NLSP N/A
- Revenue
- CARV $22,032,000.00
- NLSP N/A
- Revenue This Year
- CARV N/A
- NLSP N/A
- Revenue Next Year
- CARV N/A
- NLSP N/A
- P/E Ratio
- CARV N/A
- NLSP N/A
- Revenue Growth
- CARV N/A
- NLSP N/A
- 52 Week Low
- CARV $1.30
- NLSP $1.30
- 52 Week High
- CARV $3.85
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- CARV 61.85
- NLSP 42.28
- Support Level
- CARV $2.40
- NLSP $1.81
- Resistance Level
- CARV $2.83
- NLSP $2.15
- Average True Range (ATR)
- CARV 0.15
- NLSP 0.19
- MACD
- CARV 0.02
- NLSP -0.02
- Stochastic Oscillator
- CARV 80.83
- NLSP 13.57
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.